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Introduction {#bph14434-sec-0005}
============

Non‐alcoholic fatty liver disease (NAFLD) is characterized by massive triglyceride (TG) accumulation in the liver and can range from simple fatty liver (steatosis) to non‐alcoholic steatohepatitis (NASH), which is defined as hepatic steatosis with hepatocyte damage and inflammation (Ahmed *et al*., [2015](#bph14434-bib-0004){ref-type="ref"}). NASH may further progress to cirrhosis, liver failure and hepatocellular carcinoma (Ahmed *et al*., [2015](#bph14434-bib-0004){ref-type="ref"}). Despite the growing prevalence and incidence of NAFLD, definitive therapy for NAFLD and, more specifically, for NASH, has not yet been established (Younossi *et al*., [2016](#bph14434-bib-0059){ref-type="ref"}).

Thiazolidinediones (TZDs), agonists of <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=595&familyId=86&familyType=NHR>, are an attractive candidate therapy for NAFLD/NASH. TZDs including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1056> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2694> reduce hyperlipidaemia and hyperglycaemia and improve insulin resistance, which are strongly associated with NAFLD (Spiegelman, [1998](#bph14434-bib-0046){ref-type="ref"}). TZDs have provided histological benefit by improving steatosis and inflammation in many clinical trials (Promrat *et al*., [2004](#bph14434-bib-0038){ref-type="ref"}; Belfort *et al*., [2006](#bph14434-bib-0007){ref-type="ref"}; Sanyal *et al*., [2010](#bph14434-bib-0041){ref-type="ref"}; Cusi *et al*., [2016](#bph14434-bib-0013){ref-type="ref"}). TZDs also increase fat storage in adipose tissue, leading to the sensitization of liver and peripheral tissues to insulin (Lehrke and Lazar, [2005](#bph14434-bib-0029){ref-type="ref"}). In addition, TZDs promote production of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3726>, which is a well‐recognized anti‐diabetic adipokine and is associated with improved insulin sensitivity and hepatic fat accumulation through enhancement of <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=593&familyId=86&familyType=NHR> and <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1540> activity, fatty acid oxidation and insulin signalling (Yamauchi *et al*., [2002](#bph14434-bib-0055){ref-type="ref"}; Kadowaki *et al*., [2006](#bph14434-bib-0022){ref-type="ref"}; Awazawa *et al*., [2011](#bph14434-bib-0005){ref-type="ref"}; Blüher, [2012](#bph14434-bib-0009){ref-type="ref"}). More recently, the sirtuins, a family of NAD ‐dependent deacetylases and ADP‐ribosyltransferases, have been suggested to be a crucial regulator of beneficial TZD‐mediated metabolic effects in the liver (Shen *et al*., [2010](#bph14434-bib-0043){ref-type="ref"}; Yang *et al*., [2011](#bph14434-bib-0056){ref-type="ref"}; Yang *et al*., [2014](#bph14434-bib-0057){ref-type="ref"}).

However, information regarding metabolite changes related to TZD treatment is limited (Watkins *et al*., [2002](#bph14434-bib-0054){ref-type="ref"}; Rull *et al*., [2014](#bph14434-bib-0040){ref-type="ref"}; Meierhofer *et al*., [2014](#bph14434-bib-0033){ref-type="ref"}). To understand the metabolic effects and mechanisms of TZD treatment in NAFLD/NASH disease models, comprehensive MS‐based metabolomics studies on tissues and biological fluids are needed. Recently, a metabolomics approach has been used to identify metabolic changes and mechanisms in the organs and biofluids of animal models after the administration of food, medicine or a single compound (Jung *et al*., [2015](#bph14434-bib-0021){ref-type="ref"}; Park *et al*., [2015](#bph14434-bib-0037){ref-type="ref"}; Suh *et al*., [2016](#bph14434-bib-0048){ref-type="ref"}; Zhang *et al*., [2016](#bph14434-bib-0060){ref-type="ref"}). Moreover, metabolomics studies integrated other omics data, such as genomics and transcriptomics, allowing further insight into the mechanisms of obesity‐related disease treatment (Rull *et al*., [2014](#bph14434-bib-0040){ref-type="ref"}; Meierhofer *et al*., [2014](#bph14434-bib-0033){ref-type="ref"}; Takahashi *et al*., [2014](#bph14434-bib-0050){ref-type="ref"}; Aw and Fukuda, [2015](#bph14434-bib-0051){ref-type="ref"}).

In this study, we performed metabolomic and lipidomic profiling of liver tissue to determine the mechanisms of action of the TZD pioglitazone in the treatment of NAFLD in a rat model of obesity and Type 2 diabetes. To clarify the effects of TZDs, we further interpreted metabolome data and lipid metabolism‐related gene expression.

Methods {#bph14434-sec-0006}
=======

Animals {#bph14434-sec-0007}
-------

All animal experiments were performed in accordance with the criteria of the 'Guide for the Care and Use of Laboratory Animals' published by the US National Institutes of Health (National Research Council, [1996](#bph14434-bib-0035){ref-type="ref"}) and approved by the Ethics Committee for Animal Experiments of Kangbuk Samsung Hospital, Sungkyunkwan University. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny *et al*., [2010](#bph14434-bib-0025){ref-type="ref"}; McGrath and Lilley, [2015](#bph14434-bib-0032){ref-type="ref"}).

Male Otsuka Long‐Evans Tokushima Fatty (OLETF) rats (150--200 g, 4 weeks old) were purchased from Otsuka Pharmaceutical (Tokushima, Japan). These rats, which develop spontaneous obesity and diabetes mellitus, were used as a model of NAFLD (Kawano *et al*., [1992](#bph14434-bib-0024){ref-type="ref"}). Because of a <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=76> defect, the rats exhibit hyperphagia, hyperglycaemia and obesity and ultimately develop histological changes comparable to NAFLD in the liver (Song *et al*., [2013](#bph14434-bib-0045){ref-type="ref"}). Rats were housed in individual cages using heated wood chip litter as bedding material in a pathogen‐free environment and maintained in a temperature‐ and humidity‐controlled room (24 ± 2°C and 60% humidity) with a 12‐h light/dark cycle and fed standard irradiated rodent chow (11% kcal fat; LabDiet, St. Louis, MO, USA) and water *ad libitum*. Body weight and food intake were measured every week. At the age of 7 weeks, rats weighing 250--300 g were randomly divided into two groups: the control group (*n* = 10) and the treatment group (*n* = 8). To investigate the metabolic effects of pioglitazone on hepatic steatosis, we fed the animals a high‐fat diet (60% kcal fat, Research Diets, New Brunswick, NJ, USA) and administered either vehicle as a control or pioglitazone (30 mg·kg^−1^·day^−1^) as a treatment *via* stomach gavage daily for 12 weeks. The order of treatment was randomized. Pioglitazone was dissolved in 0.5% sodium carboxymethyl cellulose as a vehicle. There were no experimental losses related to toxic events following pioglitazone treatment. At the end of the experiment, rats were fasted overnight and deeply anaesthetized with an overdose of isoflurane. Blood was collected from the abdominal aorta, and then tissues were immediately dissected, weighed and stored at −80°C until further analysis.

Measurement of glucose tolerance and insulin sensitivity {#bph14434-sec-0008}
--------------------------------------------------------

The glucose tolerance test (GTT) was carried out after an 18‐h fast. For GTT, rats were orally administered glucose solution (2 g·kg^−1^ body weight), and blood glucose levels were measured at baseline and 15, 30, 60, 90 and 120 min after injection using the automated glucocard X‐Meter (Arkray, Kyoto, Japan). The insulin tolerance test (ITT) was also carried out after an 18‐h fast. For the ITT, rats were given an i.p. injection of human insulin (1 U·kg^−1^ body weight), and blood glucose levels were measured at baseline and 15, 30, 60, 90 and 120 min after injection. The AUC was calculated.

Metabolic parameters {#bph14434-sec-0009}
--------------------

Plasma glucose and insulin were analysed by enzymic assay (Sigma‐Aldrich, St. Louis, MO, USA and Crystal Chem, Downers Grove, IL, USA). Blood and liver TG levels were also measured by enzymic assay (Sigma‐Aldrich). Commercial kits were employed for the measurement of free fatty acids (Wako Pure Chemical Industries, Osaka, Japan) and total cholesterol (Cayman Chemical Com., Ann Arbor, MI, USA). Liver metabolic parameters were normalized to respective liver weights.

Histological analysis and NAFLD activity score {#bph14434-sec-0010}
----------------------------------------------

Dissected liver tissues were fixed in 10% formalin buffer overnight. The tissues were then embedded in paraffin, sliced into 4‐μm‐thick sections and stained with haematoxylin and eosin (H&E). Digital images were captured with an Olympus BX51 light microscope (100× magnification; Tokyo, Japan). A pathologist blinded to the experimental conditions evaluated the NAFLD activity score (NAS). Three features of NAFLD (steatosis, lobular inflammation and ballooning) were scored as described previously (Chang *et al*., [2015](#bph14434-bib-0010){ref-type="ref"}). NAS was calculated as the sum of scores for steatosis (0--3), ballooning (0--2) and inflammation (0--3).

Gene expression analysis {#bph14434-sec-0011}
------------------------

Total RNA was extracted from tissues using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). RNA was subsequently reverse‐transcribed to cDNA using a High‐Capacity RNA‐to‐cDNA Kit (Applied Biosystems, Foster City, CA, USA), according to the manufacturer\'s instructions. Gene expression levels were analysed by real‐time PCR using the LightCycler 480 System (Roche Diagnostics, Indianapolis, IN, USA) based on SYBR Green fluorescence signals, as described previously. The primer sequences used are listed in Supporting Information Table [S1](#bph14434-supitem-0001){ref-type="supplementary-material"}. The PCR parameters were as follows: pre‐denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 10 s, annealing at 55°C for 10 s and extension at 72°C for 20 s. mRNA expression of each target was normalized to glyceraldehyde‐3‐phosphate dehydrogenase as an internal control and expressed as fold change relative to the control group.

PLA~2~ activity assay {#bph14434-sec-0012}
---------------------

Rat tissues were homogenized in cold PBS at pH 7.4 and centrifuged at 10 000× *g* for 15 min at 4°C. The supernatants were collected, and the intracellular activity of <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=275> was measured with the EnzChek^®^ Phospholipase A~2~ Assay Kit (Invitrogen).

Lipid peroxidation measurement {#bph14434-sec-0013}
------------------------------

Malondialdehyde (MDA), a product of lipid peroxidation, was measured with the OxiSelect™ TBARS Assay Kit (Cell Biolabs, San Diego, CA, USA) according to the manufacturer\'s instructions. The extent of lipid peroxidation was expressed in μmol·mg^−1^ protein.

Metabolomic analysis {#bph14434-sec-0014}
--------------------

Each liver sample (100 mg) was extracted with 1 mL of 50% cold methanol (methanol : water, v/v) and 10 μL of internal standard (2‐chlorophenylalanine, 0.5 mg·mL^−1^) using an MM400 mixer mill (Retsch^®^, Haan, Germany) at a frequency of 30 s^−1^ for 10 min with a zirconium bead. After cold centrifugation (12 578× *g* for 10 min), the supernatant was filtered through a 0.2‐μm polytetrafluoroethylene filter and evaporated using a speed vacuum concentrator (Modulspin 31, Biotron, Korea). The final concentration of each sample was 5 mg·mL^−1^ using methanol for MS analysis. Gas chromatography‐time of flight (GC‐TOF)‐MS analysis was performed according to Jung *et al*. ([2015](#bph14434-bib-0021){ref-type="ref"}), and 1 μL of derivatized samples was injected in splitless mode. Ultra‐performance LC‐quadrupole (UPLC‐Q)‐TOF‐MS analysis was processed as previously described by Suh *et al*. ([2016](#bph14434-bib-0048){ref-type="ref"}), and 5 μL of sample was injected into UPLC‐Q‐TOF‐MS. Identification of metabolites with MS/MS fragmentation were provided in the [Supporting Information Data S1](#bph14434-supitem-0002){ref-type="supplementary-material"}.

Lipidomic analysis {#bph14434-sec-0015}
------------------

For lipidomic analysis, each liver sample (100 mg) was extracted with 1 mL of solvent mixture (chloroform/methanol, 1:2, v/v) using a mixer mill (MM400, Retsch) at a frequency of 30 s^−1^ for 2 min. After a 1‐h incubation at room temperature, 300 μL of chloroform and 450 μL of water were added, vortexed and centrifuged (1000× *g*, 10 min, 4°C). The lower (organic) phase was transferred to new tube, and the upper phase was re‐extracted using 600 μL of chloroform. After vortexing and centrifugation, the lower phase was transferred to a new tube. Pooled chloroform extracts were dried to complete dryness for lipid profiling. Each dried extract was reconstituted in 100 μL of solvent mixture (methanol/chloroform, 9:1, v/v) and diluted 50‐fold with methanol/chloroform (9/1, v/v) containing 7.5 mM ammonium acetate. Lipid profiling was performed using Thermo LTQ XL ion trap MS (Thermo Fisher Scientific, West Palm Beach, FL, USA) as previously described by Shon *et al*. ([2015](#bph14434-bib-0044){ref-type="ref"}). A detailed information of lipid metabolites with MS/MS fragmentation were already constructed and provided in LipidBlast libraries (Kind *et al*., [2013](#bph14434-bib-0028){ref-type="ref"}).

Measurement of total phospholipids {#bph14434-sec-0016}
----------------------------------

Separation of phospholipids *via* one‐dimensional TLC was performed according to Leray *et al*. ([1987](#bph14434-bib-0030){ref-type="ref"}). After spraying with primuline solution on a TLC plate, we checked fluorescent spots under UV light using gel documentation.

Data and statistical analysis {#bph14434-sec-0017}
-----------------------------

The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis *et al*., [2015](#bph14434-bib-0012){ref-type="ref"}). Metabolomics and lipidomics data were analysed by an analyst blinded to treatment status. Data were expressed as mean ± SD. Significant differences between groups (*P* value) were evaluated using PASW statistics 18 software (SPSS Inc., Chicago, IL, USA) *via* non‐parametric tests with the Mann--Whitney test. For metabolomics statistical analysis, GC‐TOF‐MS and UPLC‐Q‐TOF‐MS raw data were converted to NetCDF format (\*.cdf) using LECO Chroma TOF™ software (version 4.44, LECO Corp., St. Joseph, MI, USA) and MassLynx DataBridge (version 4.1, Waters Corp., Milford, MA, USA) respectively. After raw file conversion, peak alignment was processed using MetAlign software (version 041012, <http://www.metalign.nl>). Alignment of spectral data obtained from ion trap mass spectrometer was performed using Genedata Expressionist MSX (Genedata AG, Basel, Switzerland). Metabolomics and lipidomics data were normalized using an internal standard. Multivariate statistical analysis including PCA and OPLS‐DA was performed using SIMCA P+ (version 12.0, Umetrics, Umea, Sweden). Significant differences between groups (*P* value) were evaluated using PASW statistics 18 software (SPSS Inc.) *via* non‐parametric tests with the Mann--Whitney Test. A heat map was constructed using MeV software (version 4.8.1, <http://www.tm4.org>). Fold change was calculated as the ratio of the difference between the experimental and the control groups to identify any trends in the effects of pioglitazone.

Materials {#bph14434-sec-0018}
---------

Pioglitazone was obtained as a gift from Takeda Pharmaceutical (Tokyo, Japan). All chemicals and solvents used in this study were of analytical reagent grade. Freshly distilled water was used throughout the experiments.

Nomenclature of targets and ligands {#bph14434-sec-0019}
-----------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding *et al*., [2018](#bph14434-bib-0017){ref-type="ref"}), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander *et al*., [2017a](#bph14434-bib-0001){ref-type="ref"}, [2017b](#bph14434-bib-0002){ref-type="ref"}, [2017c](#bph14434-bib-0003){ref-type="ref"}).

Results {#bph14434-sec-0020}
=======

Effects of pioglitazone on metabolic parameters {#bph14434-sec-0021}
-----------------------------------------------

After 3 months on a high‐fat diet, rats fed with pioglitazone gained significantly more body weight compared with rats fed with vehicle (control), in agreement with earlier studies (Tang *et al*., [1999](#bph14434-bib-0052){ref-type="ref"}; Kawaguchi *et al*., [2004](#bph14434-bib-0023){ref-type="ref"}; Collino *et al*., [2010](#bph14434-bib-0011){ref-type="ref"}). Total fat weight to body weight ratios for pioglitazone‐treated rats was significantly higher than that of control rats (Table [1](#bph14434-tbl-0001){ref-type="table"}), consistent with the previous finding that TZDs including pioglitazone lead to increased fat storage into adipose tissue. There was a significant increase in subcutaneous fat and epididymal fat in rats that were treated with pioglitazone (Table [1](#bph14434-tbl-0001){ref-type="table"}), while mesenteric and retroperitoneal fat were not significantly different from those of control rats. Rats treated with pioglitazone showed a 25% reduction in the AUC for the glucose tolerance test and a 45% reduction in the AUC for the insulin tolerance test compared with control rats (Figure [1](#bph14434-fig-0001){ref-type="fig"}). Pioglitazone administration also reduced blood glucose levels by 20% (Table [1](#bph14434-tbl-0001){ref-type="table"}). Levels of plasma TG (25%) and free fatty acids (31%) significantly decreased in pioglitazone‐treated rats compared with control rats, and a less dramatic decrease in plasma total cholesterol level was observed (14%) (Table [1](#bph14434-tbl-0001){ref-type="table"}).

###### 

The effects of pioglitazone on metabolic parameters

                                                Control (*n* = 10)   Pioglitazone (*n* = 8)
  --------------------------------------------- -------------------- -----------------------------------------------------
  Body weight (g)                               --                   --
  Baseline                                      345.6 ± 15.6         350.3 ± 4.5
  Final                                         715.9 ± 27.7         828.6 ± 44.5[a](#bph14434-note-0003){ref-type="fn"}
  Weight change                                 370.3 ± 25.4         478.3 ± 44.3[a](#bph14434-note-0003){ref-type="fn"}
  Food intake (g)                               20.4 ± 2.0           18.4 ± 2.2
  Fat pad weight (%)                            17.6 ± 1.2           18.9 ± 0.7[a](#bph14434-note-0003){ref-type="fn"}
  Subcutaneous fat (%)                          4.7 ± 0.6            5.9 ± 0.5[a](#bph14434-note-0003){ref-type="fn"}
  Epididymal fat (%)                            3.3 ± 0.2            3.6 ± 0.3[a](#bph14434-note-0003){ref-type="fn"}
  Mesenteric fat (%)                            1.9 ± 0.3            1.9 ± 0.3
  Retroperitoneal fat (%)                       7.7 ± 0.9            7.2 ± 0.8
  Liver weight (%)                              2.8 ± 0.1            2.2 ± 0.1[a](#bph14434-note-0003){ref-type="fn"}
  Plasma glucose (mM)                           6.2 ± 0.4            5.1 ± 0.3[a](#bph14434-note-0003){ref-type="fn"}
  Plasma insulin (pM)                           288.0 ± 104.7        344.5 ± 41.9
  Plasma adiponectin (ng·mL^−1^)                3.6 ± 0.5            5.8 ± 0.5[a](#bph14434-note-0003){ref-type="fn"}
  Plasma triglycerides (mM)                     1.0 ± 0.2            0.8 ± 0.1[a](#bph14434-note-0003){ref-type="fn"}
  Plasma free fatty acids (μM)                  442.6 ± 119.3        279.4 ± 74.5[a](#bph14434-note-0003){ref-type="fn"}
  Plasma total cholesterol (mM)                 2.9 ± 0.4            2.5 ± 0.2[a](#bph14434-note-0003){ref-type="fn"}
  Liver triglycerides (μmol·g^−1^ liver)        127.8 ± 19.1         95.4 ± 35.9[a](#bph14434-note-0003){ref-type="fn"}
  Liver free fatty acids (μmol·g^−1^ liver)     8.5 ± 2.6            5.8 ± 1.3[a](#bph14434-note-0003){ref-type="fn"}
  Liver total cholesterol (μmol·g^−1^ liver)    6.9 ± 0.6            6.8 ± 0.9
  Liver malondealdehyde (μmol·mg^−1^ protein)   41.9 ± 10.1          35.8 ± 3.7[a](#bph14434-note-0003){ref-type="fn"}

Data are expressed as the mean ± SD. Control: HFD (*n* = 10); pioglitazone: 30 mg·kg^−1^ pioglitazone + HFD (*n* = 8). Fat pad weight and liver weights are expressed as a percentage of fasted body weight. Data are expressed as the mean ± SD (*n* = 10 for the control group; *n* = 8 for the PIO‐treated group).

*P* \< 0.05, significantly different from the control group. HFD, high‐fat diet.

![Effects of pioglitazone on oral glucose tolerance (OGTT), intraperitoneal insulin tolerance (ipITT) and hepatic steatosis. Effects of pioglitazone (PIO) on OGTT (A and B) and ipITT (C and D). Representative H&E liver sections (E, scale bar, 200 μm). The NAFLD activity score (NAS) is shown in F. Data are expressed as the mean ± SD; *n* = 10 for control group, *n* = 8 for PIO‐treated group. ^\*^ *P* \< 0.05, significantly different from control.](BPH-175-3610-g001){#bph14434-fig-0001}

Effects of pioglitazone on hepatic steatosis {#bph14434-sec-0022}
--------------------------------------------

Despite the observed increase in body weight, the liver weight to body weight ratio was significantly decreased in pioglitazone‐treated rats compared with control rats (Table [1](#bph14434-tbl-0001){ref-type="table"}). As shown in Figure [1](#bph14434-fig-0001){ref-type="fig"}E, F, on histological analysis using H&E staining, control livers exhibited an accumulation of lipid droplets in most hepatocytes with features of both macrovesicular and microvesicular steatosis, diffuse hepatocyte ballooning and foci of inflammatory cell infiltrates throughout the lobules, indicating that a high‐fat diet resulted in severe steatosis. Pioglitazone administration significantly decreased the degree of steatosis, ballooning, lobular inflammation and total NAFLD activity score compared with vehicle treatment. Levels of hepatic TGs and free fatty acids were significantly attenuated in pioglitazone‐treated rats compared with control rats (Table [1](#bph14434-tbl-0001){ref-type="table"}). However, there was no significant difference in the level of total cholesterol in the livers of pioglitazone‐treated rats. The degree of lipid peroxidation based on the level of MDA, a product of lipid peroxidation, was lower in pioglitazone‐treated rat livers compared with control rat livers (Table [1](#bph14434-tbl-0001){ref-type="table"}).

Hepatic metabolite analysis {#bph14434-sec-0023}
---------------------------

To identify the hepatic metabolites influenced by pioglitazone administration, we performed comprehensive metabolite profiling of rat liver using GC‐TOF‐MS, UPLC‐Q‐TOF‐MS and nanomate‐LTQ‐MS analyses with multivariate statistical analysis. The robustness and reproducibility of the MS analysis were ascertained by analysing the sample extracts in blocks of 10 runs followed by an injection of quality control sample made with pooled samples. The analytical samples were subjected to randomized runs in each block. Further, the potential analytical biases generated while sample preparation and chromatographic runs were minimized through employing the internal standards for data normalization, generating the adjusted quantitative parameters for identified metabolites.

The PCA score plot from the UPLC‐Q‐TOF‐MS dataset exhibited distinct clustering for each group, while that from GC‐TOF‐MS and nanomate‐LTQ‐MS datasets showed overlap between the two groups (Supporting Information Figure [S1](#bph14434-supitem-0001){ref-type="supplementary-material"}). As shown in Figure [2](#bph14434-fig-0002){ref-type="fig"}, the orthogonal partial least squares discriminant analysis (OPLS‐DA) score plots for liver samples from GC‐TOF‐MS (Figure [2](#bph14434-fig-0002){ref-type="fig"}A), UPLC‐Q‐TOF‐MS (Figure [2](#bph14434-fig-0002){ref-type="fig"}B) and nanomate‐LTQ‐MS (Figure [2](#bph14434-fig-0002){ref-type="fig"}C) datasets showed significant separation between control and pioglitazone groups. The fitness and prediction values of the OPLS‐DA model were evaluated using R2X, R2Y, Q2 and *P* values. In this study, a total of 131 metabolites were identified, and the relative level of each metabolite was converted into fold‐change in Tables [2](#bph14434-tbl-0002){ref-type="table"} and [3](#bph14434-tbl-0003){ref-type="table"}. The levels of most amino acids, fatty acids and some carbohydrates (arabinose, adonitol, glucuronic acid, lactose and maltose) were relatively decreased by pioglitazone treatment compared with the control group. The levels of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2796> (PE) and lysophospholipids, with the exception of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5652> (lysoPE) with C18:0 and two forms of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508> (lysoPC) with C16:0 and C18:0, were also decreased by pioglitazone treatment, while most TG levels were increased in the control group than in the pioglitazone treatment group.

![Orthogonal partial least squares discriminant analysis (OPLS‐DA) score plots from GC‐TOF‐MS, UPLC‐Q‐TOF‐MS and nanomate‐LTQ‐MS data and significantly altered hepatic metabolites between control and pioglitazone‐treated groups. OPLS‐DA score plots from GC‐TOF‐MS (A), UPLC‐Q‐TOF‐MS (B) and nanomate‐LTQ‐MS (C) data and significantly altered hepatic metabolites between control and pioglitazone(PIO)‐treated groups (D--F); *n* = 10 for control group, *n* = 8 for PIO‐treated group. Metabolites selected based on VIP \> 0.7 and *P* \< 0.05, from the OPLS‐DA model. VIP, variable importance in projection.](BPH-175-3610-g002){#bph14434-fig-0002}

###### 

Identification of liver metabolites from GC‐TOF‐MS and UPLC‐Q‐TOF‐MS combined with multivariate analysis

  GC‐TOF‐MS                                                                                                                                                             
  ------------------------ ------------------------------------------------------ ------ ------ ------ ----- ---------------------------------------------------------- --------
  Amino acids                                                                                                                                                           
  5.44                     Alanine                                                2TMS   0.41   0.93   116   73, 116, 147, 190                                          STD/MS
  6.63                     Valine                                                 2TMS   1.10   0.83   144   73, 100, 144, 218                                          STD/MS
  7.18                     Leucine[a](#bph14434-note-0005){ref-type="fn"}         2TMS   1.69   0.72   158   73, 15, 148, 158, 205, 299                                 STD/MS
  7.40                     Isoleucine[a](#bph14434-note-0005){ref-type="fn"}      2TMS   1.03   0.76   100   59, 73, 86, 100, 114, 158, 178, 218, 232                   STD/MS
  7.45                     Proline[a](#bph14434-note-0005){ref-type="fn"}         2TMS   1.50   0.65   216   73, 100, 142, 216                                          STD/MS
  7.53                     Glycine                                                3TMS   0.59   0.93   174   59, 73, 86, 100, 117, 133, 147, 158, 174, 248, 276         STD/MS
  8.02                     Serine                                                 3TMS   0.43   0.92   218   59, 73, 100, 116, 133, 147, 174, 188, 204, 218, 278        STD/MS
  8.27                     Threonine                                              3TMS   0.65   0.87   117   57, 73, 86, 101, 117, 147, 203, 219, 291                   STD/MS
  9.41                     Aspartic acid                                          3TMS   0.52   0.67   232   73, 100, 147, 188, 202, 218, 232                           STD/MS
  9.46                     5‐Oxoproline                                           2TMS   0.36   0.97   156   59, 73, 84, 100, 133, 147, 156, 230, 258                   STD/MS
  9.70                     Cysteine                                               3TMS   1.15   0.66   220   59, 73, 100, 116, 132, 147, 163, 204, 220, 294             STD/MS
  10.19                    Glutamic acid[a](#bph14434-note-0005){ref-type="fn"}   3TMS   1.74   0.68   128   56, 73, 84, 100, 114, 128, 147, 204, 230, 246, 258, 348    STD/MS
  10.29                    Phenylalanine                                          2TMS   0.94   0.83   218   59, 73, 100, 117, 130, 147, 160, 177, 192, 204, 218, 266   STD/MS
  11.67                    Ornithine                                              4TMS   0.28   0.94   130   59, 73, 86, 100, 130, 142, 174                             STD/MS
  Organic compounds                                                                                                                                                     
  4.89                     Pyruvic acid[a](#bph14434-note-0005){ref-type="fn"}    1TMS   1.43   0.74   174   59, 73, 89, 99, 115, 158, 174, 189                         STD/MS
  5.00                     Lactic acid                                            2TMS   0.71   1.07   117   73, 117, 147, 191                                          STD/MS
  6.96                     Urea                                                   2TMS   0.30   1.06   189   66, 73, 87, 100, 115, 130, 147, 157, 171, 189              STD/MS
  7.84                     Fumaric acid                                           2TMS   0.99   1.27   245   73, 147, 217, 245                                          STD/MS
  Fatty acids and lipids                                                                                                                                                
  13.08                    Palmitic acid                                          1TMS   1.01   0.84   117   73, 117, 129, 185, 313                                     STD/MS
  14.11                    Linoleic acid                                          1TMS   1.20   0.79   103   67, 103, 117, 129, 147, 262, 337                           STD/MS
  14.27                    Stearic acid                                           1TMS   0.33   0.92   117   55, 73, 117, 129, 145, 185, 201, 341                       STD/MS
  19.68                    Cholesterol                                            1TMS   0.94   0.67   129   73, 129, 213, 255, 329, 368, 458                           STD/MS
  Carbohydrates                                                                                                                                                         
  10.71                    Arabinose[a](#bph14434-note-0005){ref-type="fn"}       4TMS   1.53   0.74   103   59, 73, 89, 103, 117, 133, 147, 189, 217                   STD/MS
  10.93                    Xylitol[a](#bph14434-note-0005){ref-type="fn"}         5TMS   1.09   1.21   103   59, 73, 103, 147, 217                                      STD/MS
  11.06                    Adonitol[a](#bph14434-note-0005){ref-type="fn"}        5TMS   1.35   0.77   217   59, 73, 89, 103, 129, 147, 189, 217, 319                   STD/MS
  12.35                    Glucose[a](#bph14434-note-0005){ref-type="fn"}         5TMS   1.67   1.57   205   59, 73, 89, 103, 117, 147, 189, 205, 229, 319              STD/MS
  12.78                    Glucuronic acid                                        5TMS   0.41   0.88   333   59, 73, 89, 103, 129, 147, 292, 333                        STD/MS
  16.82                    Lactose                                                8TMS   0.52   0.86   204   73, 103, 147, 169, 204, 243, 271, 305, 361                 STD/MS
  17.17                    Maltose[a](#bph14434-note-0005){ref-type="fn"}         8TMS   1.42   0.72   204   59, 73, 103, 129, 147, 204, 243, 271, 291, 319, 361        STD/MS
  Nucleosides                                                                                                                                                           
  15.60                    Uridine[a](#bph14434-note-0005){ref-type="fn"}         3TMS   1.58   0.69   217   73, 103, 147, 169, 191, 217, 259, 299, 445                 STD/MS
  Others                                                                                                                                                                
  6.21                     Phosphoric acid                                        2TMS   0.87   0.86   241   73, 89, 119, 133, 147, 163, 181, 195, 211, 225, 241, 256   STD/MS

  UPLC‐Q‐TOF‐MS                                                                                                             
  --------------- ------------------------------------------------------ ---------- ------ ------ ----- ------------ ------ -----
  5.50            Taurine‐conjugated cholic acid                         514.2845   --     1.09   515   C26H45NO7S   2      Lib
  6.16            Taurine‐conjugated deoxycholic acid                    498.2913   --     1.21   499   C26H45NO6S   2.4    Lib
  6.29            Taurine‐conjugated cholic acid                         514.2871   --     1.24   515   C26H45NO7S   5      Lib
  7.74            Taurine‐conjugated deoxycholic acid                    498.2892   --     0.91   499   C26H45NO6S   0      Lib
  8.15            LysoPE (22:6)[a](#bph14434-note-0005){ref-type="fn"}   524.2798   1.38   0.06   525   C27H44NO7P   4      Lib
  8.18            LysoPC (22:6)[a](#bph14434-note-0005){ref-type="fn"}   552.3109   1.63   0.44   567   C30H50NO7P   −3.4   Lib
  8.21            LysoPC (18:2)[a](#bph14434-note-0005){ref-type="fn"}   504.3125   1.90   0.48   519   C26H50NO7P   −0.8   Lib
  8.23            LysoPC (20:4)[a](#bph14434-note-0005){ref-type="fn"}   528.3077   1.58   0.63   543   C28H50NO7P   3.9    Lib
  8.28            LysoPE (22:6)                                          524.2784   1.05   0.68   525   C27H44NO7P   −1.2   Lib
  8.31            LysoPC (22:6)                                          552.3093   0.33   0.93   567   C30H50NO7P   −3.9   Lib
  8.35            LysoPE (20:4)                                          500.2786   0.08   0.98   501   C25H44NO7P   −3.6   Lib
  8.37            LysoPC (20:4)                                          528.3110   0.81   0.93   543   C28H50NO7P   1.4    Lib
  8.39            LysoPC (18:2)[a](#bph14434-note-0005){ref-type="fn"}   504.3115   1.18   0.80   519   C26H50NO7P   −2.9   Lib
  8.62            LysoPC (16:0)                                          480.3119   0.61   1.22   495   C24H50NO7P   1.7    Lib
  8.79            LysoPE (16:0)                                          452.2778   0.45   1.20   453   C21H44NO7P   −3.5   Lib
  8.83            LysoPC (16:0)                                          480.3086   0.47   1.15   495   C24H50NO7P   3.3    Lib
  8.87            LysoPC (18:1)[a](#bph14434-note-0005){ref-type="fn"}   506.3289   1.68   0.42   521   C26H52NO7P   3.6    Lib
  9.06            LysoPC (18:1)                                          506.3273   0.01   1.00   521   C26H52NO7P   −0.1   Lib
  9.69            LysoPC (18:0)                                          508.3431   1.14   1.60   523   C26H54NO7P   0.3    Lib
  9.89            LysoPC (18:0)                                          508.3390   1.08   1.47   523   C26H55NO7P   −2.8   Lib

ID, identification; HMDB, The Human Metabolome Database (<http://www.hmdb.ca>); Lib, in house library; MS, mass fragments pattern; RT, retention time; STD, standard compounds; TMS, trimethylsilyl; VIP, variable importance in projection.

Metabolites showing significant differences (VIP \> 0.7 and *P* value \<0.05) between experimental groups.

###### 

Identification of liver metabolites *via* nanomate‐LTQ‐MS combined with multivariate analysis

  No.   Metabolites                                      Identified ion (*m/z*)   VIP    Adduct   Fold‐change[b](#bph14434-note-0008){ref-type="fn"} (PIO/Control)
  ----- ------------------------------------------------ ------------------------ ------ -------- ------------------------------------------------------------------
  1     CE 18:3                                          664.6                    1.20   NH4+     0.77
  2     CE 20:2                                          694.5                    0.39   NH4+     1.09
  3     CE 20:3                                          692.6                    0.44   NH4+     1.07
  4     CE 20:4                                          690.5                    0.48   NH4+     1.10
  5     CE 20:5                                          688.5                    0.07   NH4+     0.99
  6     DG 34:1                                          612.4                    0.02   NH4+     1.00
  7     DG 34:2                                          610.3                    0.02   NH4+     1.00
  8     DG 36:1                                          640.6                    1.28   NH4+     1.25
  9     PC 32:1                                          754.6                    0.47   Na+      1.03
  10    PC 32:2                                          752.6                    0.29   Na+      0.97
  11    PC 34:0                                          784.8                    1.07   Na+      0.92
  12    PC 34:1                                          782.7                    0.62   Na+      0.95
  13    PC 34:2                                          780.7                    0.19   Na+      1.02
  14    PC 34:3                                          778.6                    0.06   Na+      1.00
  15    PC 35:0                                          798.7                    0.73   Na+      1.11
  16    PC 36:0                                          790.7                    1.49   H+       0.89
  17    PC 36:1[a](#bph14434-note-0007){ref-type="fn"}   788.8                    1.82   H+       0.86
  18    PC 36:2[a](#bph14434-note-0007){ref-type="fn"}   786.7                    1.87   H+       0.88
  19    PC 36:3[a](#bph14434-note-0007){ref-type="fn"}   806.7                    1.14   Na+      0.91
  20    PC 36:4                                          804.7                    0.30   Na+      0.95
  21    PC 36:5                                          802.7                    0.68   Na+      1.05
  22    PC 38:5                                          808.7                    0.72   H+       0.95
  23    PC 38:2                                          814.8                    0.96   H+       0.94
  24    PC 38:3                                          812.8                    0.88   H+       0.94
  25    PC 38:4                                          810.7                    1.02   H+       0.93
  26    PC 38:6                                          828.7                    0.58   Na+      0.90
  27    PC 38:7                                          826.7                    0.58   Na+      1.06
  28    PC 40:2[a](#bph14434-note-0007){ref-type="fn"}   842.7                    1.76   H+       1.17
  29    PC 40:4[a](#bph14434-note-0007){ref-type="fn"}   860.7                    2.30   Na+      1.39
  30    PE 36:4[a](#bph14434-note-0007){ref-type="fn"}   762.8                    2.36   Na+      0.86
  31    PE 38:3                                          770.6                    0.44   H+       0.96
  32    PE 38:4                                          768.6                    0.45   H+       0.95
  33    PE 38:5                                          766.6                    1.21   H+       0.91
  34    PE 38:6[a](#bph14434-note-0007){ref-type="fn"}   764.5                    2.04   H+       0.83
  35    TG 42:0                                          740.5                    0.08   NH4+     1.01
  36    TG 46:0                                          796.7                    0.09   NH4+     1.01
  37    TG 46:1                                          794.7                    1.41   NH4+     0.89
  38    TG 46:2                                          792.6                    1.30   NH4+     0.85
  39    TG 48:0                                          824.7                    0.06   NH4+     1.00
  40    TG 48:1[a](#bph14434-note-0007){ref-type="fn"}   822.7                    1.58   NH4+     1.27
  41    TG 48:2                                          820.6                    0.98   NH4+     1.27
  42    TG 48:3                                          818.7                    0.48   NH4+     1.03
  43    TG 49:0[a](#bph14434-note-0007){ref-type="fn"}   838.8                    1.63   NH4+     0.88
  44    TG 49:1                                          836.7                    0.84   NH4+     0.94
  45    TG 49:2                                          834.7                    0.57   NH4+     0.96
  46    TG 50:0                                          852.8                    1.41   NH4+     1.32
  47    TG 50:1[a](#bph14434-note-0007){ref-type="fn"}   850.7                    1.55   NH4+     1.42
  48    TG 50:2[a](#bph14434-note-0007){ref-type="fn"}   848.7                    2.17   NH4+     1.36
  49    TG 50:3[a](#bph14434-note-0007){ref-type="fn"}   846.7                    2.22   NH4+     1.69
  50    TG 50:4[a](#bph14434-note-0007){ref-type="fn"}   844.6                    1.53   NH4+     1.37
  51    TG 51:1                                          864.7                    1.32   NH4+     1.19
  52    TG 52:0                                          880.8                    1.00   NH4+     1.20
  53    TG 52:1                                          878.8                    0.98   NH4+     1.50
  54    TG 52:2                                          876.7                    1.07   NH4+     1.57
  55    TG 52:3                                          874.7                    1.14   NH4+     1.57
  56    TG 52:4                                          872.7                    1.12   NH4+     1.49
  57    TG 52:5                                          870.7                    1.44   NH4+     1.65
  58    TG 53:1                                          892.7                    1.40   NH4+     1.29
  59    TG 53:2                                          890.7                    1.50   NH4+     1.41
  60    TG 53:3                                          888.7                    1.34   NH4+     1.37
  61    TG 53:4                                          886.6                    1.45   NH4+     1.29
  62    TG 54:3                                          902.7                    0.81   NH4+     1.39
  63    TG 54:4                                          900.7                    0.80   NH4+     1.37
  64    TG 54:5                                          898.7                    0.78   NH4+     1.34
  65    TG 54:6                                          896.7                    0.88   NH4+     1.39
  66    TG 55:0                                          922.7                    0.50   NH4+     1.21
  67    TG 55:1                                          920.7                    0.61   NH4+     1.26
  68    TG 55:2                                          918.7                    0.86   NH4+     1.25
  69    TG 55:3                                          916.7                    0.71   NH4+     1.09
  70    TG 55:4                                          914.7                    0.90   NH4+     1.12
  71    TG 55:5                                          912.7                    1.21   NH4+     1.21
  72    TG 56:1                                          934.7                    0.10   NH4+     1.01
  73    TG 56:3                                          930.7                    0.19   NH4+     0.97
  74    TG 56:4                                          928.8                    0.64   NH4+     1.23
  75    TG 56:6                                          924.7                    0.48   NH4+     1.21
  76    TG 57:2                                          946.7                    0.11   NH4+     1.04
  77    TG 57:3                                          944.6                    0.16   NH4+     1.06
  78    TG 57:4                                          942.7                    0.10   NH4+     0.98
  79    TG 58:5                                          954.8                    0.03   NH4+     0.99
  80    TG 58:6                                          952.7                    0.02   NH4+     1.01

VIP, variable importance in the projection.

Significantly different from OPLS‐DA models, based on VIP value (\>0.7) and *P* \<0.05.

Relative levels of metabolites were converted into fold‐change.

Hepatic metabolites that were discriminant between groups were selected based on the variable importance in projection value (\>0.7) from each OPLS‐DA model and the *P* value (\<0.05) from non‐parametric testing. Twenty‐eight metabolites, including four amino acids, one organic acid, four carbohydrates, six lysophospholipids, seven phospholipids, five TGs and uridine, were significantly different between groups (Figure [2](#bph14434-fig-0002){ref-type="fig"}). The levels of most amino acids and carbohydrates, except glucose and xylitol, were significantly down‐regulated in pioglitazone‐treated rats (Figure [2](#bph14434-fig-0002){ref-type="fig"}D). However, two carbohydrates (glucose and xylitol), two phosphatidylcholines (PCs) (40:2 and 40:4), and most TGs, except TG (49:0), were significantly up‐regulated in control rats compared to pioglitazone‐treated rats. In particular, we observed a marked alteration in lipid metabolism‐related metabolites (fatty acids, cholesterol, lysoPCs, lysoPEs, PCs, PEs and TGs) in the liver. According to Figure [2](#bph14434-fig-0002){ref-type="fig"}D--F, most fatty acids, lysoPCs with a relatively long acyl chain (≥18) and a double bond and phospholipids with a relatively short acyl chain (\<39) were significantly decreased in the pioglitazone‐treated group compared with the control group.

Effect of pioglitazone on phospholipase activity and phospholipid biosynthesis {#bph14434-sec-0024}
------------------------------------------------------------------------------

Lysophospholipids are mainly generated from PLA~2~‐catalysed hydrolysis of phospholipids (Balsinde *et al*., [1999](#bph14434-bib-0006){ref-type="ref"}). Therefore, to further explain the observed decreases in lysoPC levels in pioglitazone‐treated livers, we determined PLA~2~ gene expression and its activity in the liver. Among the various subtypes of PLA~2~, we measured the activity of cytosolic PLA2α (cPLA2α), the enzyme that catalyses the hydrolysis of membrane phospholipids to liberate lysophospholipids and arachidonic acid (C20:4), which is subsequently metabolized into eicosanoids (Balsinde *et al*., [1999](#bph14434-bib-0006){ref-type="ref"}). As shown in Figure [3](#bph14434-fig-0003){ref-type="fig"}A, B, pioglitazone treatment significantly decreased cPLA2α activity and tended to reduce mRNA expression of PLA2G4A, the gene encoding cPLA2α. Furthermore, we determined whether phospholipid biosynthesis was affected by pioglitazone treatment. First, we measured total PC and PE content in the liver using TLC. As shown in Figure [3](#bph14434-fig-0003){ref-type="fig"}C, TLC analysis revealed that hepatic total PC content was decreased in pioglitazone‐treated rats compared with control rats, whereas total PE levels in the liver were not altered among control and pioglitazone‐treated groups. We also measured the mRNA levels of all lysophosphatidylcholine acyltransferase (LPCAT) family members, which catalyse the synthesis of PC from lysoPC (Zhao *et al*., [2008](#bph14434-bib-0061){ref-type="ref"}), in the livers of control and pioglitazone‐treated rats. Figure [3](#bph14434-fig-0003){ref-type="fig"}D showed that LPCAT3 is the most abundant isoform of this family in the liver, and there was a lower trend in the mRNA expression of LPCAT3 in the pioglitazone‐treated group, i.e., this difference was not statistically significant. Therefore, livers of pioglitazone‐treated rats had decreased pool of phospholipid, especially PC, while LPCAT enzymes, which re‐synthesize PC from lysoPC, were not affected.

![Effects of pioglitazone on hepatic PLA~2~ activity phospholipid biosynthesis and gene expression related to hepatic fatty acid metabolism. Effects of pioglitazone (PIO) on hepatic PLA~2~ activity (A), PLA2G4a gene expression (B), total phospholipid amounts (C), LPCAT gene expression (D) and gene expression related to hepatic fatty acid metabolism (E). Data are expressed as mean ± SD; *n* = 10 for control group, *n* = 8 for PIO‐treated group. ^\*^ *P* \< 0.05, significantly different from control. ACC1α, acetyl‐CoA carboxylase 1α; CPT1α, carnitine palmitoyltransferase 1α; DGAT, diglyceride acyltransferase; FAS, fatty acid synthase; CD36/FAT, fatty acid translocase; FATP1, fatty acid transport protein 1; aP2/FABP4, fatty acid binding protein 4; LXRα, liver X receptor α; SREBP1c, sterol regulatory element‐binding protein 1c; SCD1, stearoyl‐CoA desaturase‐1.](BPH-175-3610-g003){#bph14434-fig-0003}

Hepatic expression of genes related to fatty acid metabolism {#bph14434-sec-0025}
------------------------------------------------------------

We further investigated whether pioglitazone affects gene expression involved in fatty acid metabolism (Figure [3](#bph14434-fig-0003){ref-type="fig"}E). First, we determined the expression of genes involved in *de novo* lipogenesis. Pioglitazone down‐regulated expression of sterol regulatory element‐binding protein 1c (SREBP1c), the master regulator of lipogenesis, and stearoyl‐CoA desaturase‐1 (SCD1), key enzymes for the synthesis of monounsaturated fatty acids (MUFAs) from saturated fatty acids (Liu *et al*., [2015](#bph14434-bib-0031){ref-type="ref"}). Gene expression of <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=602> and <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2821&familyId=844&familyType=ENZYME> 1 and 2, all of which are related to hepatic *de novo* lipogenesis, was decreased or trended lower in pioglitazone‐treated groups compared with control groups respectively. However, mRNA levels of two other SREBP1c‐target genes<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2608> and <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=255#1263>, were up‐regulated or similar to those of untreated rats respectively. Next, we investigated whether pioglitazone increased fatty acid oxidation, thereby reducing fat accumulation in rat livers. The mRNA levels of PPAR‐α and its target gene, carnitine palmitoyltransferase 1α, showed a trend towards higher values in pioglitazone‐treated rats, compared with control rats.. We also observed that expression of genes involved in uptake and transport of fatty acids, especially long‐chain fatty acids (carbons 12--20), including <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1108> and <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2534> (also called adipocyte protein 2, aP2), was significantly down‐regulated in the livers of the pioglitazone group. Thus, these observations could account for a decrease in free fatty acids, which can be taken up by hepatocytes and activate PPAR‐γ signalling in the liver. On the other hand, fatty acid translocase/CD36 mRNA expression was up‐regulated in the liver by pioglitazone treatment. Therefore, these results indicated that pioglitazone treatment may result in decreased availability of fatty acids for hepatic *de novo* lipogenesis and increased fatty acid oxidation, decreasing the accumulation of lipid in the liver.

Discussion {#bph14434-sec-0026}
==========

In this study, we found that pioglitazone treatment improved the plasma lipid profile including circulating free fatty acids and TGs, glucose tolerance and liver histology in OLETF rats fed a high‐fat diet, consistent with the results from previous studies (Tang *et al*., [1999](#bph14434-bib-0052){ref-type="ref"}; Kawaguchi *et al*., [2004](#bph14434-bib-0023){ref-type="ref"}; Collino *et al*., [2010](#bph14434-bib-0011){ref-type="ref"}). We also observed that pioglitazone treatment resulted in alteration of hepatic metabolite and lipid profiles related to metabolic parameters. Furthermore, we found that pioglitazone regulates the metabolic pathways involved in hepatic *de novo* lipogenesis, fatty acid transport and oxidation and lysophospholipid biosynthesis, which are involved in metabolite and lipid profile shifts, thus improving hepatic steatosis.

NAFLD is highly prevalent and strongly associated with metabolic disorders such as obesity, diabetes and cardiovascular disease. Recently, metabolomic studies, defined as the comprehensive quantitative and qualitative analysis of all metabolites in objects including cells, tissues or biofluids, have been performed to investigate metabolomic components related to the formation of hepatic steatosis in humans and animals (Nicholson *et al*., [1999](#bph14434-bib-0034){ref-type="ref"}; Beyoğlu and Idle, [2013](#bph14434-bib-0008){ref-type="ref"}). Compared with non‐steatotic livers, lipid species including cholesterol esters, TGs, diacylglycerols and sphingomyelins were elevated in steatotic liver (Beyoğlu and Idle, [2013](#bph14434-bib-0008){ref-type="ref"}). In addition, phosphocholine, choline, betaine and trimethylamine N‐oxide were up‐regulated in both the liver and the plasma of rodents with diet‐induced fatty liver, indicating an increased turnover of PC and PE species in the liver, thus releasing free fatty acids through the action of PLAs (Toye *et al*., [2007](#bph14434-bib-0053){ref-type="ref"}; Beyoğlu and Idle, [2013](#bph14434-bib-0008){ref-type="ref"}). Furthermore, increased hepatic levels of lysoPC, lysoPE and PC species have been reported for steatotic livers compared with non‐steatotic livers in humans and rodents (García‐Cañaveras *et al*., [2011](#bph14434-bib-0014){ref-type="ref"}; Han *et al*., [2017](#bph14434-bib-0015){ref-type="ref"}).

Our metabolomic and lipidomic analysis revealed that pioglitazone treatment significantly altered several hepatic metabolites and lipids including free fatty acids, lysophospholipids and phospholipids. Some of our results from metabolomic/lipidomic analysis were coincident with the earlier findings, whereas others were not. In the previous studies, levels of numerous long‐chain fatty acids such as saturated fatty acids (e.g. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377>) and MUFA (e.g. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5547> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054>) were positively affected by a high‐fat diet (Kim *et al*., [2011](#bph14434-bib-0026){ref-type="ref"}; Liu *et al*., [2015](#bph14434-bib-0031){ref-type="ref"}). In our study, we observed that pioglitazone decreased palmitic acid and stearic acid, which suggests its role as a mediator of lipotoxicity. We could not detect hepatic MUFA in this study due to the small samples used for metabolomic analysis. However, it is conceivable that MUFA production may be decreased in the pioglitazone group *via* reduction of saturated fatty acids and SCD1 expression. In addition, expression of genes involved in long‐chain fatty acid uptake and transport and hepatic *de novo* lipogenesis was decreased. These findings suggest the attenuation of hepatic *de novo* lipogenesis following pioglitazone treatment.

A recent study has demonstrated elevation in lysoPCs, especially the fatty acyl group of C16:0 and C18:3, in human steatotic liver tissues (García‐Cañaveras *et al*., [2011](#bph14434-bib-0014){ref-type="ref"}). In another study on human livers, a significant increase in the level of lysoPC with C20:4 was observed in human samples during NAFLD progression (Han *et al*., [2017](#bph14434-bib-0015){ref-type="ref"}). Increased hepatic lysophospholipids have been reported in *db*/*db* mice and may cause insulin resistance (Han *et al*., [2011](#bph14434-bib-0016){ref-type="ref"}). Also, a high‐fat diet increased numerous hepatic lysophospholipids in mice (Kim *et al*., [2011](#bph14434-bib-0026){ref-type="ref"}; Kim *et al*., [2014](#bph14434-bib-0027){ref-type="ref"}; Liu *et al*., [2015](#bph14434-bib-0031){ref-type="ref"}). In the present study, pioglitazone treatment significantly decreased most hepatic lysoPCs, except those lysoPCs with fatty acyl groups of C16:0 and C18:0. Lower levels of cytosolic PLA2α activity and PLA2G4A mRNA expression in the pioglitazone‐treated group indicated a reduced potential for biosynthesis of lysophospholipids and release of free fatty acids. Meanwhile, adiponectin treatment reversed high‐fat diet‐induced increases in lysophospholipid levels in mouse liver (Liu *et al*., [2015](#bph14434-bib-0031){ref-type="ref"}). Given the observation of a significant increase in circulating adiponectin in the pioglitazone group, we cannot rule out the possibility that the effects of TZDs on lysophospholipid levels were mediated by adiponectin.

Although many studies have indicated that levels of lysoPCs are closely associated with oxidative stress and inflammation (Nishi *et al*., [1998](#bph14434-bib-0036){ref-type="ref"}; Stock *et al*., [2006](#bph14434-bib-0047){ref-type="ref"}; Schilling and Eder, [2010](#bph14434-bib-0042){ref-type="ref"}), this effect depends on the length and unsaturation of the fatty acyl group (Riederer *et al*., [2010](#bph14434-bib-0039){ref-type="ref"}; Hung *et al*., [2011](#bph14434-bib-0019){ref-type="ref"}). LysoPCs containing an unsaturated fatty acyl group such as C20:4 and C22:6 showed potent anti‐inflammatory activity in *in vivo* and *in vitro* models (Huang *et al*., [2010](#bph14434-bib-0018){ref-type="ref"}; Hung *et al*., [2011](#bph14434-bib-0019){ref-type="ref"}; Hung *et al*., [2012](#bph14434-bib-0020){ref-type="ref"}). Interestingly, lysoPC containing C16:0, which has pro‐inflammatory properties, enhanced glucose uptake in an insulin‐independent and <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1485&familyId=533&familyType=ENZYME>‐dependent manner in adipocytes and to have a glucose‐lowering effect in Type 1 and Type 2 diabetes mouse models (Yea *et al*., [2009](#bph14434-bib-0058){ref-type="ref"}). Activation of PPAR‐α also induced hepatic lysoPC (16:0) production and secretion (Takahashi *et al*., [2015](#bph14434-bib-0049){ref-type="ref"}). In addition, lysoPC (16:0) activated PPAR‐α and induced the expression of PPAR‐α target genes (Takahashi *et al*., [2015](#bph14434-bib-0049){ref-type="ref"}). Therefore, further study is needed to investigate the functions of lysoPCs in metabolic regulation.

Hepatic levels of PC species and turnover of PC and PE species are increased in steatotic livers (Toye *et al*., [2007](#bph14434-bib-0053){ref-type="ref"}; García‐Cañaveras *et al*., [2011](#bph14434-bib-0014){ref-type="ref"}; Han *et al*., [2011](#bph14434-bib-0016){ref-type="ref"}; Beyoğlu and Idle, [2013](#bph14434-bib-0008){ref-type="ref"}). In the present study, we observed that pioglitazone treatment significantly altered the amount and fatty acyl composition of hepatic phospholipids, in particular, PCs, as well as the total PC amount in the liver. Unlike rosiglitazone, which was previously reported not to alter the total concentration of PC in the liver (Watkins *et al*., [2002](#bph14434-bib-0054){ref-type="ref"}), pioglitazone treatment significantly reduced total PC in the rat liver. In addition, we found a relative decrease in palmitic acid (C16:0) in PC composition. However, given the lack of significant changes in gene expression of LPCAT, which resynthesizes PC from lysoPC, we cannot conclude that pioglitazone affects the turnover of PCs in the liver, and further investigation of this potential interaction is needed.

In summary, we have demonstrated here that pioglitazone changed hepatic metabolite and lipid profiles and regulated relevant metabolic pathways, which may explain the beneficial effect of pioglitazone on hepatic steatosis, induced by a high‐fat diet in OLETF rats (Figure [4](#bph14434-fig-0004){ref-type="fig"}). Pioglitazone reduced hepatic fatty acid levels not only by down‐regulating hepatic *de novo* synthesis of fatty acids but also by disrupting uptake and transport of exogenous fatty acids, which may contribute to a reduction in the availability of fatty acids for TG and phospholipid biosynthesis. In addition, pioglitazone treatment lowered the function of PLA~2~, but not LPCAT, leading to decreased production of lysophospholipids. Pioglitazone also increased fatty acid oxidation. These changes may help to decrease lipid accumulation in the liver.

![Scheme of the mechanism by which pioglitazone (PIO) regulates hepatic metabolites, lipids and related gene‐expression patterns (italicized). All metabolites, lipids and related gene‐expression patterns in the PIO‐treated groups compared to the control groups are illustrated in the heat map. Pioglitazone down‐regulates hepatic *de novo* synthesis of fatty acids and disrupts uptake and transport of exogenous fatty acids, which may contribute to reduced availability of fatty acids for TG and phospholipid biosynthesis in the liver. In addition, pioglitazone treatment lowers the function of PLA~2~, but not LPCAT, leading to decreased production of lysophospholipids. Pioglitazone also increases fatty acid oxidation. These changes may contribute to the decreased accumulation of lipid in the liver. The pathway was modified from KEGG (<http://www.genome.jp/kegg>). FFA, free fatty acid; FA transporter, fatty acid transporter.](BPH-175-3610-g004){#bph14434-fig-0004}

One limitation of this study is the absence of a normal diet‐fed control group for comparison of hepatic metabolites. However, we validated the high‐fat diet‐induced development and improvement in hepatic steatosis by pioglitazone treatment in OLETF rats using physiological and histological assessments. Our data indicated that pioglitazone treatment changed hepatic metabolites and lipids associated with lipid metabolism in a NAFLD model, which may act as targets for diagnosis and clinical intervention in patients with NAFLD.
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